Abstract 3620
Background
BAY 1436032 (BAY) inhibits R132X-mIDH1, which aberrantly generates oncometabolite 2-hydroxyglutarate (2-HG). In animal studies, BAY decreased 2-HG levels in mIDH1 tumours and showed brain penetration (brain/plasma ratio ∼0.2). Plasma 2-HG levels are increased in pts with mIDH1 tumours like intrahepatic cholangiocarcinoma (IHCC), but not in mIDH1 gliomas.
Methods
In this ongoing phase I dose-escalation and expansion study, BAY was administered orally (150-1500 mg BID) to pts with advanced mIDH1-R132X solid tumours. 4 expansion cohorts (1500 mg BID) enrolled pts with anaplastic and advanced grade 2 gliomas, glioblastoma (GBM), IHCC and other tumours. Response was assessed by RECIST (solid tumours) and RANO criteria (gliomas). Plasma BAY and 2-HG levels were measured.
Results
29 pts were treated in the escalation part in 5 dose-escalation cohorts and 52 in the expansion part. Pts had glioma (n = 55), IHCC (n = 16), chondrosarcoma (n = 7) and other tumours (n = 3). As of the 8 Nov 2018 preliminary cut-off, the most common all-cause treatment-emergent AEs reported in ≥ 10% of pts were: headache (20%), vomiting, diarrhoea and fatigue (19% each), nausea (16%), ALT increased (12%) and blood bilirubin increased (11%). There was 1 DLT (grade 3 rash maculopapular, 1500 mg BID). MTD was not reached; RP2D was 1500 mg BID. BAY exposure increased broadly dose proportionally from 150-1200 mg, with high variability. Consistent with short half-life, no accumulation was observed. Plasma 2-HG reduction occurred in nearly all non-glioma pts, with up to 98% inhibition. A pt with anaplastic astrocytoma (AA) (1200 mg BID) achieved complete response and is still on treatment (>23 months at cut-off); 2 glioma pts (AA and oligodendroglioma, both 1500 mg BID) had a partial response. 6 additional pts remained on treatment with stable disease at cut-off (3 gliomas, 2 GBM, 1 IHCC; treatment duration 4-11 months). Updated safety, efficacy and PK/PD analyses will be presented.
Conclusions
BAY is well tolerated as anticipated due to specificity for mIDH1. BAY inhibited mIDH1-R132X activity as evidenced by a PD effect in pts with measurable 2-HG, with objective response in 3 pts (all gliomas).
Clinical trial identification
NCT02746081.
Editorial acknowledgement
Medical writing assistance was provided by Laura Valenzo, PhD, of Complete Health Vizion and funded by Bayer AG.
Legal entity responsible for the study
Bayer AG.
Funding
Bayer AG.
Disclosure
W. Wick: Non-remunerated activity/ies, patent: IDH vaccine; Non-remunerated activity/ies, patent: IDH diagnostic; Non-remunerated activity/ies, patent: APG diagnostic. G. Tabatabai: Research grant / Funding (self): Roche Diagnostics; Research grant / Funding (self): Medac; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Novocure; Travel / Accommodation / Expenses: Medac; Speaker Bureau / Expert testimony: Medac; Speaker Bureau / Expert testimony: Novocure; Advisory / Consultancy: AbbVie; Advisory / Consultancy: BMS; Advisory / Consultancy: TIGER NIS (Novocure); Advisory / Consultancy: ON-TRK NIS (Bayer). M. Schuler: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Novartis; Advisory / Consultancy: Roche; Honoraria (self): Abbvie; Honoraria (self): Alexion; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Celgene; Honoraria (self): Lilly; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Pierre Fabre; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Bristol Myers-Squibb; Research grant / Funding (institution): Novartis. K. Rorhberg: Research grant / Funding (self), Non-remunerated activity/ies: Bayer; Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Roche; Research grant / Funding (self), Non-remunerated activity/ies: Loxo Oncology; Research grant / Funding (self), Non-remunerated activity/ies: Orion Pharma; Research grant / Funding (self), Non-remunerated activity/ies: Pfizer; Research grant / Funding (self), Non-remunerated activity/ies: PUMA; Research grant / Funding (self), Non-remunerated activity/ies: Cantargia; Research grant / Funding (self), Non-remunerated activity/ies: Genmab; Research grant / Funding (self), Non-remunerated activity/ies: Novartis; Research grant / Funding (self), Non-remunerated activity/ies: Incyte; Research grant / Funding (self), Non-remunerated activity/ies: Symphogen; Research grant / Funding (self), Non-remunerated activity/ies: AstraZeneca; Research grant / Funding (self), Non-remunerated activity/ies: Alligator; Research grant / Funding (self), Non-remunerated activity/ies: Merck; Travel / Accommodation / Expenses: Sanofi; Research grant / Funding (self), Non-remunerated activity/ies: BMS. S.P. Chawla: Research grant / Funding (self): Amgen; Research grant / Funding (self): Roche; Research grant / Funding (self): Threshold Pharmaceuticals; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Immune Design; Research grant / Funding (self): TRACON Pharma; Research grant / Funding (self): SARC; Research grant / Funding (self): Karyopharma Therapeutics; Research grant / Funding (self): Jansen. F. Janku: Research grant / Funding (self): Novartis; Research grant / Funding (self): Genentech; Research grant / Funding (self): Bayer; Research grant / Funding (self): BioMed Valley Discoveries; Research grant / Funding (self): Astellas; Research grant / Funding (self): Agios; Research grant / Funding (self): Plexxikon; Research grant / Funding (self): Deciphera; Research grant / Funding (self): Piqur; Research grant / Funding (self): Symphogen; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Asana; Research grant / Funding (self): Upsher-Smith Laboratories; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: IFM Therapeutics; Advisory / Consultancy: Synlogic; Advisory / Consultancy: Deciphera; Advisory / Consultancy: Trovagene; Advisory / Consultancy: Immunomet; Shareholder / Stockholder / Stock options: Trovagene. Y. Narita: Speaker Bureau / Expert testimony, Research grant / Funding (self): Chugai Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ono Pharmaceutical; Speaker Bureau / Expert testimony, Research grant / Funding (self): Abbvie; Speaker Bureau / Expert testimony, Research grant / Funding (self): Dainippon-Sumitomo; Speaker Bureau / Expert testimony, Research grant / Funding (self): Daiichi-Sankyo; Speaker Bureau / Expert testimony, Research grant / Funding (self): Eisai; Speaker Bureau / Expert testimony, Research grant / Funding (self): Stella-pharma; Speaker Bureau / Expert testimony, Research grant / Funding (self): Ohtuka; Speaker Bureau / Expert testimony, Research grant / Funding (self): Meiji-seika; Speaker Bureau / Expert testimony, Research grant / Funding (self): SBI pharma. Y. Ando: Honoraria (self), Research grant / Funding (self): Chugai Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Kyowa Hakko Kirin Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Nippon Kayaku Co., Ltd.; Honoraria (self), Research grant / Funding (self): Yakult Honsha Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Eli Lilly Japan K.K.; Honoraria (self), Research grant / Funding (self): Mochida Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Ono Pharmaceutical Co.,Ltd.; Honoraria (self), Research grant / Funding (self): Taiho Pharmaceutical Co.,Ltd.; Honoraria (self): Novartis Pharma K.K.; Honoraria (self): Merck Serono Co.,Ltd.; Honoraria (self): Bayer Holding Ltd.; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Otsuka Holdings Co.,Ltd.; Honoraria (self): Sawai Pharmaceutical Co., Ltd; Honoraria (self), Research grant / Funding (self): Daiichi Sankyo Company, Ltd.; Research grant / Funding (self): Eisai Co.,Ltd.; Research grant / Funding (self): Hisamitsu Pharmaceutical Co., Inc.; Research grant / Funding (self): Takeda Pharmaceutical Co.,Ltd.; Honoraria (self): Tsumura & Co.; Honoraria (self): Shionogi & Co.,Ltd; Honoraria (self): Janssen Pharmaceutical K.K.; Honoraria (self): Pharma International Inc. H.J. Lenz: Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Bayer; Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony: Merck KG. M. Ikeda: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Bayer; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eisai; Honoraria (self), Advisory / Consultancy: MSD; Research grant / Funding (self): Ono; Advisory / Consultancy, Research grant / Funding (self): ASLAN; Honoraria (self), Research grant / Funding (self): Yakult; Research grant / Funding (self): J-Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Eli Lilly; Honoraria (self), Research grant / Funding (self): Sumitomo Dainippon; Research grant / Funding (self): Kowa; Honoraria (self): Abbott; Honoraria (self): EA Pharma; Advisory / Consultancy, Research grant / Funding (self): Chugai; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Novartis; Honoraria (self), Advisory / Consultancy: Teijin Pharma; Advisory / Consultancy, Research grant / Funding (self): Kyowa Hakko Kirin; Advisory / Consultancy, Research grant / Funding (self): NanoCarrier; Advisory / Consultancy: Shire; Honoraria (self), Research grant / Funding (self): Taiho; Research grant / Funding (self): AstraZeneca; Research grant / Funding (self): Baxalta; Research grant / Funding (self): Merck Serono; Advisory / Consultancy, Research grant / Funding (self): Takara Bio; Research grant / Funding (self): Zeria; Honoraria (self): Nobelpharma; Honoraria (self), Advisory / Consultancy: Otsuka; Honoraria (self): Kaken Pharmaceutical; Honoraria (self): Gilead; Advisory / Consultancy: Astellas Pharma; Research grant / Funding (self): Takeda Pharmaceutical; Advisory / Consultancy: Micron. I. Genvresse: Full / Part-time employment: Bayer AG. C. Rentzsch: Full / Part-time employment: Bayer AG. S. Reschke: Full / Part-time employment: Bayer AG. C. Cyris: Full / Part-time employment: CHRESTOS Concept GmbH & Co. KG. C. Cai: Full / Part-time employment: Bayer HealthCare Pharmaceuticals, Inc. M. Jeffers: Full / Part-time employment: Bayer HealthCare Pharmaceuticals, Inc. C. Peña: Full / Part-time employment: Bayer HealthCare Pharmaceuticals, Inc. O. Bähr: Honoraria (self): Novocure; Honoraria (self): Medac Pharma; Honoraria (self): BMS. All other authors have declared no conflicts of interest.
Resources from the same session
3690 - PD-L1 expression in resected undifferentiated pleomorphic sarcoma and its clinical implications
Presenter: Kyoungmin Lee
Session: Poster Display session 1
Resources:
Abstract
2013 - PD-L1 expression as a potential therapeutic target and prognostic biomarker in well-differentiated and dedifferentiated liposarcoma.
Presenter: Heejung Chae
Session: Poster Display session 1
Resources:
Abstract
5021 - Soft tissue sarcomas express a distinct mRNA immune profile
Presenter: Viktor Grünwald
Session: Poster Display session 1
Resources:
Abstract
3029 - The molecular landscape of fusion genes in endometrial stromal sarcomas include three nosological entities with different natural history
Presenter: Mehdi Brahmi
Session: Poster Display session 1
Resources:
Abstract
3914 - Clinical validation of a novel assay for the detection of diagnostic alterations in sarcomas
Presenter: Lauren Mc Connell
Session: Poster Display session 1
Resources:
Abstract
1912 - A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS).
Presenter: Kanan Alshammari
Session: Poster Display session 1
Resources:
Abstract
5097 - Fusion of immortalized myoblasts induces genomic instability that drives tumor development and progression.
Presenter: Candice Merle
Session: Poster Display session 1
Resources:
Abstract
1383 - let-7a suppress Ewing sarcoma CSCs' malignant phenotype through forms a positive feedback regulation loop with lin28 via STAT3
Presenter: Xu Jiang
Session: Poster Display session 1
Resources:
Abstract
3386 - Myoepithelial Tumors of Soft Tissues and Extraskeletal Myxoid Chondrosarcomas feature a distinct transcriptional pattern
Presenter: Dominga Racanelli
Session: Poster Display session 1
Resources:
Abstract
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract